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ABSTRACT
In this study we attempted to determine the molecular mechanisms underlying 
the two mature products of pre-miR-140 (3p and 5p) in malignant properties of 
lung cancer cells. The differential expression of the two forms of miR-140 in both 
NSCLC tissues and cell lines was determined by quantitative real-time PCR (qRT-
PCR). The effects of the miR-140 mimics on the malignant properties of lung cancer 
cells were evaluated using invasion assay, adhesion assay, tubule formation assay 
and metabolite profiling. Biotin-miRNA pulldown and transcriptome profiling by RNA-
seq were utilized to distinguish their mRNA targets of the miR-140 strands. Their 
downstream signalling pathways were unveiled using a high-throughput antibody 
array. Although both strands of the miR-140 are downregulated in the NSCLC, miR-
140-3p is more predominant compared to miR-140-5p in lung cancer cell lines. Both 
miR-140 mimics suppress the invasion of lung cancer cells and the inhibitory effect 
of the miR-140 on adhesion is cell-dependent. Tumor conditioned media from A549 
cells after treatment with miR-140-3p mimic reduce the tubule formation ability of 
the endothelial cells. Metabolite profiling indicates the alteration of glycine in both 
lung cancer cells following treatment with miR-140 mimics. The data from the RNA-
sequencing and antibody array indicate that two miR-140 strands present different 
targeting and signalling profiles despite the existence of mutual targets such as IGF1R 
and FOS. In conclusion, two forms of miR-140 both suppress the malignant properties 
of lung cancer cells but through distinct and multiple mechanisms.
INTRODUCTION
MicroRNAs (miRNAs or miRs) are small non-
coding RNAs that prevent the translation of their 
mRNA targets into proteins. Aberrant expression levels 
of miRNAs are associated with many malignancies, 
including lung cancer, suggesting their roles as either 
oncogenes or tumour suppressors [1]. MiR-140 precursor 
is located on chromosome 16q22.1 and produces two 
mature single strands named miR-140-3p and miR-140-
5p. They were fist studied in congenital malformations, 
as changes in their expression levels during the 
embryogenesis leads to some serious developmental 
defects [2]. During miRNA biogenesis, the duplex of the 
two mature miRNA strands is produced from the hairpin 
miRNA precursor by Dicer cleavage. Then, a following 
strand selection step determines which mature miRNA 
acts as guide in the mature miRNA-mediated silencing 
complex (miRISC). However, previous studies show 
that miR-140-3p and 140-5p are both downregulated in 
different cancer cells and tissues compared to their normal 
counterparts, including lung, thus suggesting their roles as 
tumour suppressors [3–6].
Lung cancer is the most frequent cancer worldwide, 
with approximately 1.8 million new cases in 2012 (12.9% of 
the total tumour cases) [7]. Within the two types according 
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to the morphological differences of the lung cancer cells, 
Non-Small Cell Lung Cancer (NSCLC) accounts about 85-
90% of all cases and has a high tendency for developing 
distant metastases, while Small Lung Cancers (SCLC) 
comprises about 10-15% of the lung cancer cases [8].
We previously demonstrated the anti-tumour effect 
of miR-140-5p on NSCLC lung cancer cells [1]. In this 
study, the role of its sister strand miR-140-3p was further 
investigated in NSCLC in comparison with miR-140-5p. 
Following the evaluation of its expression in a NSCLC 
patient cohort, miR-140-3p was investigated for its effect 
on the malignant properties of A549 and SK-MES1 cell 
lines. The effect of tumour conditioned media (TCM) 
from lung cancer cells treated with miR-140 mimics on 
the ability of in-vitro angiogenic capacity of the primary 
endothelial cells (i.e. HUVECs) was also investigated. 
To explore the targeting and mechanisms of the miR-140 
strands in a global manner, the pulldown gene targets by 
biotin-miRNA mimics were analysed by Ion Proton RNA 
sequencing, which were integrated with the proteomic 
profile from Kinex™ Antibody Microarray with 878 
antibodies embedded.
RESULTS
MiR-140-3p is downregulated in NSCLC tissues 
and lung cancer cell lines
In the lung cancer cohort we have obtained, there 
was lower level of miR-140-3p expression in both unpaired 
(p=0.0031, Figure 1A) and paired tissues (p=0.0215, 
Figure 1B) compared to the adjacent tissues. Similarly, 
we also observed lower level of miR-140-5p expression 
in both unpaired (p=0.0034, Figure 1C) and paired tissues 
(p=0.0239, Figure 1D) compared to the adjacent tissues. 
We further investigated the expression of the both mature 
miR-140 strands in lung cancer cell lines. In accordance 
with the finding in lung cancer tissue, we found that the 
expression levels of both miR-140-3p and miR-140-5p 
were significantly downregulated in the both SK-MES-1 
(p=0.002) and A549 (p<0.0001) lung cancer cells compared 
to the normal lung epithelial cells (BEAS-2B). Also, 
there were higher levels of miR-140-3p than miR-140-5p 
produced in SK-MES-1 (p=0.001) and A549 (p<0.0001), 
whereas a differential expression of these two strands of 
miR-140 was not observed in BEAS-2B (Figure 1C).
MiR-140-3p reduces the invasion ability of 
NSCLC in vitro
To investigate the function of miR-140-3p with 
comparison with miR-140-5p in lung cancer cells, 
miRNA-140 mimics and a scramble negative control were 
transfected into lung cancer cells. As shown in Figure 2A, 
after transfection, the fold change of miR-140-3p levels in 
A549 cells was 26,508 (p<0.0001 vs Negative mimic) after 
24 h and 1737 (p<0.0001) after 48 h. Similarly, the fold 
change of miR-140-3p levels in SK-MES-1 cells was 4,084 
(p<0.0001) after 24 h and 2,757 (p<0.0001) after 48h. In 
both lung cancer cell lines, following transfection, the levels 
of miR-140-3p were significantly higher at 24 h than 48h, 
indicating the dynamic change of the miRNA mimics.
A transwell invasion assay was performed to 
evaluate whether miR-140-3p exerted any effect on the 
invasion property of lung cancer cells. As shown in Figure 
2C and 2D, transfection with miR-140-3p mimics led to 
the reduced invasion properties in A549 and SK-MES-1 
cells, with p<0.001 in both cell lines compared to the 
negative mimic controls. In contrast, there was no effect 
of miR-140-3p on migration of the lung cancer cell lines 
(Figure 2C). Also we did not observe any change in cell 
cycle and proliferation after the treatment with miR-140-
3p (Supplementary Figure 1).
After the lung cancer cells were treated with the 
miR-140-3p and miR-140-5p mimics, respectively, we also 
evaluated the cellular apoptosis level by Annexin V-FITC and 
propidium iodide (PI) staining. As shown in Supplementary 
Figure 2, there was no induction of apoptosis following the 
treatments compared to the negative mimic control.
The two strands of miR-140 alter the metabolite 
profile of lung cancer cells in a similar way
To understand whether the treatment with the miR-
140 mimics have an effect on the metabolism of lung 
cancer cells, the cells, following treatment, were subjected 
to GC-MS metabolite analysis. Within the analysis, 
131 metabolite signals were detected and compared 
following normalisation to the internal standard. As 
shown in Figure 3A, the principle component analysis 
using the full metabolite profile does not discriminate 
either of the cancer cell lines used or the normal lung 
cell line from each other or allow for separation of cell 
lines based upon treatment with a miRNA mimic. This 
suggests that at the global level there is little impact 
upon the major metabolites identified in this analysis. 
Upon performing statistical analysis upon each individual 
metabolite level (rather than studying the total profile via 
principle component analysis) a few metabolites were 
identified as generating P values less than 0.05, inferring 
a statistical difference in levels during the analysis. 
However, when studying large metabolomics datasets 
with a limited number of replicates, these differences 
(although interesting and providing significant initial 
P values) should be treated as preliminary as multiple 
hypothesis testing corrections on this scale often reduce 
their significance. For the A549 cell line only, there was 
a difference detected in three metabolites based upon 
treatment with an miRNA mimic, Figure 3B shows an 
extracted ion chromatogram for m/z 174 (representing 
the amino acid glycine), which is at very low levels in 
the A549 cell line when untreated, but elevated following 
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Figure 1: Expression of miR-140-3p in the NSCLC cohort and lung cell lines. (A) Expression of miR-140-3p in non-paired 
adjacent-normal (N) and tumour (T) tissues. (B) Expression of miR-140-3p in paired adjacent-normal (N) and tumour (T) tissues. (C) 
Expression of miR-140-5p in non-paired adjacent-normal (N) and tumour (T) tissues. (D) Expression of miR-140-5p in paired adjacent-
normal (N) and tumour (T) tissues. (E) Expression of miR-140-3p in two lung cancer cells (SK-MES-1 and A549) and BEAS-2B lung 
epithelial cells.
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Figure 2: Change of miR expression and invasion properties in lung cancer cells after transfection with miR-140-3p 
mimic. (A) Expression of miR-140-3p in A549 cells. (B) Expression of miR-140-3p in SK-MES-1 cells. (C) Transwell invasion property 
of A549 cells with response to miR-130-3p mimic. (D) Transwell invasion property of SK-MES-1 cells with response to miR-130-3p 
mimic. (E) Transwell migration property of A549 cells with response to miR-130-3p mimic. (F) Transwell migration property of SK-
MES-1 cells with response to miR-130-3p mimic. Data are presented as mean + SEM, three individual experiments were undertaken in 
triplicate, Student’s t-test was used to assess significance.
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treatment with either miRNA mimic. Only the A549 cells 
exhibited a difference in metabolite levels based upon 
treatment (compared to the untreated control cells (NEG)) 
and these metabolites and their levels are represented in 
Figure 3: The two strands of miR-140 have minor impact upon the metabolite profile of lung cancer cells. Lung cancer 
cells (A549 and SK-MES-1) and BEAS-2B lung epithelial cells were treated with miRNA mimics for 24 hours before cell samples were 
collected for metabolite analysis using Mass spectrometry (GC-MS). (A) A principle component analysis of the metabolite data set for 
the three cell lines without treatment (NEG) and with either miRNA mimic. (B) Example GCMS chromatogram of m/z 174 representing 
glycine levels in the control (NEG, black line) and after treatment with miR-140-3P (red line) and miR-140-5P (blue line). (C) Normalized 
peak area of metabolites which differed in level in A549 cells dependent on treatment. (D) Normalized peak area of metabolites which 
differed in level dependent on the cell line studied. Data are presented as mean + SEM, experiments were undertaken in triplicate, T-test 
and Mann Whitney tests were used to assess significance among multiple groups with *p<0.05, and **p<0.01.
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Figure 3C. The increase in glycine levels occurs regardless 
of which mimic is used (P< 0.01) whilst the change in 
levels of dodecane and the lanostanedione derivative differ 
dependent upon treatment with miR-140-5p or miR-140-
3p. The other cell lines did not demonstrate a statistically 
significant difference in metabolite profile dependent upon 
treatment alone. Further analysis sought to study whether 
the different cell lines used responded differently to either 
of the miRNA mimics (Figure 3D) and this analysis 
demonstrated that the vast majority of metabolites did not 
vary between cell lines with or without treatment, however 
glycine was shown to differ in level between A549 cells 
and BEAS-2B cells following treatment with either 
mimic (P<0.01) and also between SK-MES-1 and BEAS-
2B cells, but only following treatment with miR-140-5p 
(P<0.05). Malate levels were only identified as differing 
between SK-MES-1 and BEAS-2B following treatment 
with miR-140-3p (P<0.01).
The TCM from cancer cells transfected with 
miR-140 mimics inhibit the tubule formation in 
HUVECs
As shown in Figure 4, the TCM from A549 cells 
treated with miR-140-3p for 24 hours reduced the ability of 
HUVECs to form vessels including length of tubule branch 
(p<0.01, Figure 4A) and number of vessel-like meshes 
(p<0.001, Figure 4B). Likewise, the TCM from SK-MES-1 
cells treated with miR-140-3p for 24 hours also reduced 
the angiogenic ability of HUVECs including tubule length 
(p<0.001) and vessel-like mesh (p<0.0001) (Figure 4C and 
4D). The TCM from A549 cells treated with miR-140-3p 
for 48 hours also reduced the ability of HUVECs to form 
vessels including length of tubule branch (p<0.05, Figure 
4A) and number of vessel-like mesh (p<0.001, Figure 
4B). However, the 48-h CM from SK-MES-1 treated with 
miR-140-3p did not show any effect on tubule formation 
of SK-MES-1. The 24-h TCM from A549 after miR-140-
5p treatment did not show any effect on tubule formation, 
however 48-h TCM from A549 after miR-140-5p treatment 
inhibited the tubule formation of HUVECS including the 
tubule length (p<0.05) and the meshes number (p<0.01). 
The 24-h TCM from SK-MES-1 after miR-140-5p treatment 
reduced the tubule meshes number (p<0.001). However, the 
48-h TCM from SK-MES-1 after miR-140-5p did not show 
any effect on tubule formation. The representative images 
of the tubule formation of the HUVECs co-cultured with the 
TCM of lung cancer cells treated with miR-140-3p and 140-
5p mimics were shown in Supplementary Figure 3.
We further investigated whether the inhibitory effect to 
miR-140 mimics was due to any change in VEGF-A secreted 
by lung cancer cells in the TCM. As shown in Figure 4E–4H, 
the treatment with miR-140-3p and miR-140-5p, respectively, 
did not significantly change the secretion of VEGF-A in the 
TCM from the two cell lines (A549 and SK-MES-1) and at 
two time pointes (24 and 48 h).
MiR-140-3p targets ITGB3
By combining the data from the main bioinformatics 
algorithms including TargetScan and MiRWalk, we 
identified integrin-β3 (ITGB3) as a potential direct target 
of miR-140-3p. In order to verify this canonical target, 
the DNA fragment of the wild-type ITGB3 3’-UTR (wt) 
which contains the 6-mer complementary with miR-140-
3p and the mutated fragment of the ITGB3 3’-UTR (mut) 
were assembled into the pmirGLO vector, respectively.
A549 cells containing the ITGB3wt resulted in a 
significant decrease of the luciferase activity when miR-
140-3p were co-transfected compared to the vector control 
(p<0.05, Figure 5B). As a contrary, cells containing the 
ITGB3mut did not repress the activity of the luciferase, 
but, as expected, produced a signal similar to the negative 
control containing the vector only.
It is known that integrins participate in cell adhesion 
through its domain to bind ECM proteins, to indirectly 
confirm whether miR-140-3p may has an effect on cell 
adhesion through targeting ITGB3, adhesion ability of 
A549 cells was assessed after miR-140-3p treatment 
for 24 h. As shown in Figure 5C and 5D, miR-140-3p 
enhanced the adhesion property of A549 cells on laminin 
(p<0.001) and collagen (p<0.001), respectively compared 
to the control with the negative miRNA mimic.
Two miRNA-140 strands play different roles in 
gene targeting and cell signalling pathways
The integrated approaches of biotin-miRNA pulldown 
and transcriptome profiling by RNA-seq were used to screen 
the mRNA targets of the two miR-140 strands in a systematic 
manner [9]. As shown in Figure 6A, based on the criteria 
we have used, the RNA-Seq data indicate that there were 
637 unique miR-140-3p targets and 813 unique miR-140-
5p targets, and both miR-140 strands shared 1075 targets. 
When we zoomed in to compare the first and last 25 targets 
of each miR-140 strands, the RNA-Seq heatmap showed 
the different patterns of their targets. We further investigate 
the signalling pathways regulated by the two miR-140 
strands using the Kinex Antibody Array which features 880 
antibodies. As shown in Figure 6C, the heatmap indicated 
that two miRNA-140 regulated distinctive signalling patterns 
although some proteins were co-regulated.
We then attempted to integrate the data from RNA-
Seq and antibody array in order to identify more significant 
targets. As shown in Table 1, six target candidates of miR-
140-3p were identified, which included HDAC4, EGFR, 
FOS, IGF1R, RAC1 and CDK1. Within these targets 
CDK1 can be predicted by an in silico tool TarBase. 
Using the same criteria, we identified twelve miR-140-
5p targets which included SMAD3, PTEN, MAPK12, 
PRKCE, IGF1R, INSR, FOX, IRS1, MAPK14 (p38α), 
JAK1, STAT3 and CAV1 (Table 2). Within this panel of 
targets, IGF1R was predicted by MIRTARBASE, while 
JAK1 and SMAD3 could be predicted by TARBASE. 
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Figure 4: Tubule formation ability of the primary endothelial cells HUVECs co-cultured with TCM of lung cancer 
cells treated with miR-140-3p and 140-5p mimics. HUVECs were seeded onto a layer of Matrigel with completed growth medium 
supplemented with 40% TCM from miR-treated lung cancer cells for 24 and 48 hours, respectively. The tubule formation was monitored in 
real-time by using the EVOS Cell Imaging System. Images were taken every 30 minutes for 6 hours. (A) Total length of the tubule structure 
form by HUVECs in the presence of TCM from A549. (B) Number of closed mesh structure formed by HUVECs in the presence of TCM 
from A549. (C) Total length of the tubule structure form by HUVECs in the presence of TCM from SK-MES-1. (D) Number of closed mesh 
structure formed by HUVECs in the presence of TCM from SK-MES-1. Data are presented as mean + SEM, three individual experiments 
were undertaken in triplicate, Kruskal-Wallis-test was used to assess significance with *p<0.05, **p<0.01 and ***p<0.001. (E-H) Secreted 
protein level of VEGF in TCM from the two lung cancer cells after treatment with miRNA mimics for 24 and 48 hours, respectively.
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Figure 5: Validation of ITGB3 as a direct target of miR-140-3p. (A) Predicted binding sites of ITGB3 3’-UTR and miR-140-3p 
using an online tool TargetScan. The base pairing between the ITGB3 3’UTR binding site and the seed region of miR-140-3p is showed by 
vertical lines (top). The binding site of miR-140-3p and the mutated form of ITGB3 3’-UTR includes 3 nucleotides (bottom). (B) Relative 
luciferase activity levels following 24 hours transfection of A549 cells with the Luciferase reporter vector containing the backbone vector 
only, ITGB3 3’-UTR (ITGB3wt) and the mutated form of the 3’-UTR (ITGB3mut), respectively. Data are presented as fold change of the 
mean + SEM, three individual experiments were undertaken in triplicate, ANOVA-test was used to assess significance with *p<0.05. (C) 
Effect of miR-140-3p on adhesion ability of A549 cells on laminin and collagen type IV following transfection for 24 hours.
Oncotarget36482www.oncotarget.com
Figure 6: Distinctive gene regulation profiles and cell signalling pathways induced by two strands of miR-140. (A) 
Heatmap of the RNA-seq data showing the altered upregulated (red) and downregulated (green) genes in A549 treated with miR-140-3p 
and miR-140-5p, respectively. Global transcriptome analysis of 20816 gene targets was performed using the Ion AmpliSeq™ human gene 
expression panel. (B) The Venn diagram showing the differential gene expression induced by miR-140-3p and miR-140-5p, respectively, 
based on the RNA-Seq data. (C) Heatmap of the Kinex antibody array data showing the distinctive cell signalling pathways altered by the 
two strands of miR-140. The values of Z-score reflected positive or negative shifts in differential protein expression fold-changes after 
normalization by protein concentration and negative miRNA mimics. (D) Evaluation the expression of some key downstream effectors of 
miR-140-3p in A549 cells after treatments for 48 hours by Western blotting.
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Table 1: Association of RNA-Seq data after biotinylated-miRNA pull down with Kinex™ Antibody Microarray data 
from cells treated with miR-140-3p
RNA-seq Kinex™ Antibody Microarray In silico prediction
Gene target Log2(Fold change) Protein phospho site % (Change from control)
HDAC4 -0.79 Pan-specific -34.56
EGFR -0.67 Y1172 -55.69
Y1197 -52.00
FOS -0.44 T232 -33.27
IGF1R -0.40 Y1280 -33.81
RAC1 0.44 S71 -38.49
CDK1 0.51 Pan-specific -37.13 TarBase
Data were normalized using cells treated with negative mimic control. Only the molecules which have a RNA-Seq value 
less than <-0.38 or over than 0.38, and an Antibody Microarray value <-30% or >30% were selected. The calculation 
of selection criteria is: log2(1.3) equivalent to 0.38. These miRNA target prediction/validation databases were searched: 
TarBase, miRTarBase, miRWalk, miRecords, miRTar, DIANA-microT, Microrna.org and Targetscan.
Table 2: Association of RNA-Seq data after biotinylated-miRNA pull down with Kinex™ Antibody Microarray data 
from cells treated with miR-140-5p
RNA-seq Kinex™ Antibody Microarray In silico prediction
Gene target Log2(Fold change) Protein phospho site % (Change from control)
SMAD3 -1.95 Pan-specific -33.25 TARBASE
PTEN -0.55 S380+T382+T383 -44.56
MAPK12 -0.52 Pan-specific -37.01
PRKCE -0.52 S729 -36.45
IGF1R -0.49 Y1280 -40.66 MIRTARBASE
Y1165/Y1166 43.37
INSR -0.41 Y612 -47.59
Y1189/Y1190 -38.55
Y999 42.29
FOS -0.39 T232 -44.84
Pan-specific 53.27
IRS1 0.40 S639 -32.35
MAPK14 0.46 T180+Y182 -46.02
JAK1 0.50 Y1034 -30.11 TARBASE
STAT3 0.56 Y705 -43.98
CAV1 0.80 Pan-specific -30.28
Data were normalized using cells treated with negative mimic control. Only the molecules which have a RNA-Seq value 
less than <-0.38 or over than 0.38, and an Antibody Microarray value <-30% or >30% were selected. The calculation of 
selection criteria is: log2(1.3) equivalent to 0.38. These miRNA target prediction/validation databases were searched: 
TarBase, miRTarBase, miRWalk, miRecords, miRTar, DIANA-microT, Microrna.org and Targetscan.
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And IGF1R and FOS were targets of both miR-140-3p 
and miR-140-5p.
MiR-140-3p reduces the invasion properties 
of A549 cells and the angiogenic potential of 
endothelial cells through EGFR
There is evidence that ITGB3 may activate EGFR and 
p-Src in epithelial cells [10]. We further evaluated the protein 
levels of ITGB3 and EGFR signalling proteins in A549 cells. 
As shown in Figure 6D, Western blotting demonstrated the 
downregulation of ITGB3 after treatment with miR-140-3p 
in A549 cells. Furthermore, there was a decrease of EGFR 
protein level as well as its downstream checkpoint proteins 
AKT1 and ERK. However, there was a slight increase of 
PTEN, and the level of p-Src (Y530) remained unchanged.
DISCUSSION
Previous clinical studies and our cohort screening 
data indicate that both miR-140-3p and miR-140-5p are 
downregulated in NSCLC and this is associated with the 
progression of the malignancy [1, 3, 4, 11]. Also, single-
nucleotide polymorphism (SNP) or point mutation of 
the pre-miR-140 sequence may lead to the imbalanced 
formation of the two sister strands, for instance, an increase 
of miR-140-3p and decrease of miR-140-5p levels in the 
cleft palate syndrome, as the loss of targeting the Platelet-
Derived Growth Factor-A (PDGFR-A) by miR-140-5p 
occurs [12]. Our previous study showed that treatment with 
miR-140-5p mimic can reduce the invasion properties of 
lung cancer cells by inhibiting the EGFR signalling pathway 
[1]. We herein further investigated the expression and gene 
targeting of miR-140-3p in lung cancer in comparison with 
its sister strand miR-140-5p in lung cancer.
Using the same lung cancer cohort, we observed that 
miR-140-3p is also downregulated in NSCLC like miR-
140-5p. This observation is in line with the reports from 
other studies on miR-140-3p [13, 14]. Currently there is 
no report of the association of miR-130-3p with patient 
survival probably due to the lack of cohort with long follow 
up. However, lower has-miR-140-5p is linked with poorer 
overall survival of lung cancer patients (p<0.05) by an online 
tool for prognostic biomarker identification using the GEO 
and TCGA datasets (http://www.compbio.iupui.edu/progmir). 
Our data also indicate that the expression of these two strands 
of miR-140 in lung cancer cells is lower than that in normal 
lung epithelial cells BEAS-2B. In addition, in lung cancer 
cells, the expression of miR-140-3p is higher than miR-140-
5p, suggesting that the mature strand formation of the pre-
miR-140 in lung cancer cells is not even.
Using the miRNA mimics, we demonstrate that 
treatment with miR-140-3p suppresses the invasion of 
A549 and Sk-MES-1 lung cancer cells. This confirms 
the findings from other studies [4, 13]. However, our 
data indicate that miR-140-3p has no effect on migration, 
Table 3: Clinicopathological characteristics of the non-small cell lung cancer (NSCLC) cohort
Characteristic Number Percentage miR-140-3p
p-value
miR-140-5p
p-value
Gender
Female 28 41%
0.151 0.307
Male 40 59%
TNM
T1N1M0 1 1%
0.6992 0.810
T1N2M0 2 3%
T1N2M1 10 15%
T2N2M0 11 16%
T2N3M0 1 1%
T3N0M0 1 1%
T3N2M0 3 4%
Unknown 39 57%
Smoking history
Non-smokers 9 13%
0.110 0.851Smokers 34 50%
Unknown 25 37%
It included 68 cases with 19 cases of paired tumour and adjacent-normal tissues. There were 68 NSCLC and 40 adjacent-
normal tissues obtained from this cohort in total. The association of the expression of the two strands of miR-140 with the 
clinicopathological features was evaluated using Mann-Whitney U test (for Gender) or Kruskal-Wallis rank sum test (for 
TNM and Smoking history).
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proliferation of lung cancer cells, which was unlike other 
studies [4, 13]. Also miR-140-3p does not induce any 
apoptosis and cell cycle arrest in lung cancer cells.
By metabolite analysis, we show that miR-140-
3p and miR-140-5p demonstrate very little change in the 
intracellular metabolites within the cell lines, however a few 
metabolites levels were observed to have a small change in 
levels. In particular, glycine was shown to increase in the 
A549 cancer cell line following treatment with either mimic 
and miR-140-3p increases the level of one substance named 
as 18-bis(acetyloxy)Lanostane-7,11-dione, Interestingly, 
this latter metabolite substance has previously been reported 
to suppress tumor progression [15, 16]. Glycine has recently 
been reported as having a key role in cancer proliferation 
via cleavage of the amino acid by glycine decarboxylase 
and utilisation of the resulting one-carbon units to allow for 
increased mitochondrial activity [17, 18] and hence altered 
levels in cancer cells and an increase in A549 following 
treatment with miRNA mimics may reduce this metabolic 
pathway leading to elevations in uncatabolised glycine 
levels. Whilst other reports question the role of glycine 
decarboxylase in cancer proliferation, the same studies note 
that, in some tumours, glycine levels are depleted via the 
conversion of glycine to serine as an alternative pathway 
in which serine increases allow for proliferation [19]. 
The levels of malate appear to be elevated in the normal 
BEAS-2B cells compared to the cancer cell lines and this 
may represent the proposed role of increased cytosolic 
malate dehydrogenase in lung cancer patients [20] and 
the fact that treatment with either mimic does not cause 
an increase in malate levels compared to the normal lung 
cell lines, suggests that this metabolic contributor to cancer 
development is not affected by the miRNA mimics. Overall, 
however remarkably little change was seen at the metabolite 
level following the treatments utilised.
We also attempted to evaluate the ability of the 
endothelial cells HUVECs to form new vessels in response 
to the treatment of the cancer cells with miR-140-3p. The 
TCM from A549 cells treated with miR-140-3p for 24 
hours reduced the tubule formation of the endothelial cells, 
respectively. The TCM medium from A549 cells treated with 
miR-140-5p for 48 hours also reduced the tubule formation 
of HUVEC cells, although it tended to be less potent than 
the miR-140-3p TCM groups. HUVEC cells also showed 
reduced levels of vessel-like mesh structure formation 
after treatment with the 24h-hour TCM of SK-MES-1 after 
Figure 7: Schematic diagram of the proposed distinctive mechanisms that two forms of miR-140 suppress the metastatic 
properties of lung cancer cells.
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treatment with miR-140-3p and miR-140-5p, respectively. 
It is known that quite often VEGF-A plays a crucial role 
in driving angiogenesis of endothelial cells particularly in 
pathological conditions. Our ELISA data however show that 
the VEGF-A secretion in TCM from both lung cancer cells 
was not altered after treatment with the two strands of miR-
140 for 24 and 48 hours. Therefore, VEGF-A is not involved 
in the inhibitory effect of the TCM from lung cancer cells 
after treatment with the two strands of miR-140.
We then further investigated the potential targets of 
miR-140-3p in order to explain the functional alteration 
of lung cancer cells we have observed. By using a 
bioinformatics approach, we were able to identify ITGB3 
as a direct target of miR-140-3p. It has been reported that 
integrins mediate the adhesion and migration properties 
of tumour cells by cooperating with specific growth 
factor receptors, such as EGFR [10, 21]. Also integrins 
are also expressed in tumour-associated cells, including 
endothelial cells [21]. There is evidence that integrins 
regulate various pathways depending on the stimuli 
in the tumour microenvironment [21]. In particular, 
ITGB3 is associated with the tumour progression 
[22]. For example, when ITGB3 is assembled with 
the α5 integrin subunit to form the α5β3 complex, it 
can regulate angiogenesis together with other growth 
factors receptors, such as the Fibroblast Growth Factor 
Receptor (FGFR) in a Src-independent manner [23]. 
After the validation of ITGB3 as a novel direct target 
of miR-140-3p, we further demonstrated that the 
transfection with miR-140-3p mimics enhanced the 
adhesion ability of A549 on laminin and collagen, two 
of the main components of the ECM. Also, the EMT 
process is halted by miR-140-3p mimics. During EMT, 
the tumour cells lose their epithelial phenotypes and 
acquire some mesenchymal-like properties that enable 
them to survive and form metastasis in distant sites [24]. 
We focused on some EMT markers specifically involved 
in lung cancer progression [25], and found that miR-
140-3p restored the levels of E-cadherin while reduced 
the expression of N-cadherin, Vimentin, Slug and Snail. 
These findings could partly explain the alteration of 
migration and invasion of lung cancer cells with response 
to miR-140-3p.
It has been shown that miRNAs in the tumour 
microenvironment can be released by the cells 
encapsulated into either microvesicles or exosomes 
and internalised into the endothelial cells thus mediate 
angiogenesis [26–29]. We therefore speculate that miR-
140-3p exerts an inhibitory effect on HUVECs by targeting 
ITGB3 for three main reasons. First of all, ITGB3 has 
been found up-regulated in both cancer and endothelial 
cells [21]. Secondly, the miRNAs in conditioned media 
from cancer cells after miR-140-3p mimic treatment 
may be incorporated in the endothelial cells. Finally, 
Table 4: Primers used for the evaluation of miRNA expression and miRNA target validation
Primer Sequence
miR-specific RT CAGGTCCAGTTTTTTTTTTTTTTTVN
RNU6B
Forward GTCGTGAAGCGTTCCA
Reverse CAGGTCCAGTTTTTTTTTTTTTTTAAA
RNU48
Forward ACCGCAGCGCTCT
Reverse TCCAGTTTTTTTTTTTTTTTGGTCA
miR140-5p
Forward CAGCAGTGGTTTTACCCTATG
Reverse GGTCCAGTTTTTTTTTTTTTTTCTAC
miR140-3p
Forward GTACCACAGGGTAGAACCA
Reverse GTACCACAGGGTAGAACCA
ITGB3-miR-140-3P
Forward AAACTAGCGGCCGCTGAGCCACTGCCCCCGGCTGTGGTTGT
Reverse CTAGACAACCACAGCCGGGGGCAGTGGCTCAGCGGCCGCTAGTTT
ITGB3 mutated-miR-140-3P
Forward AAACTAGCGGCCGCTGAGCCACTGCCCCCGGCTAAGTTGT
Reverse CTAGACAACTTAGCCGGGGGCAGTGGCTCAGCGGCCGCTAGTTT
In the sequences of the miR-specific RT primer, V = A or G or C, N = A or G or C or T. RNU6B and RNU48 were used 
for the normalization of the miRNA expression using a Sybr Green qRT-PCR miRNA assay. The predicted ITGB3 3’UTR 
target regions complementary to miR-140-3p was designed based on the prediction by the online tool TargetScan Human 
7.0 (http://www.targetscan.org). The overhangs created by oligonucleotide annealing were designed to be complementary 
to those sites recognized by the restriction enzymes PmeI (GTTT^AAAC) and XbaI (T^CTAGA). NotI internal site 
(GC^GGCCGC) was added for cloning digestion.
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the inhibition of the tubule formation ability is VEGF-A 
independent and previous studies suggest the involvement 
of ITGB3 in angiogenesis [23].
To better understand the gene targeting and key 
signalling pathways mediated by the two strands of miR-
140, we performed RNA-seq after biotin-miRNA pull 
down and Kinex Antibody Array. The RNA-seq data 
show that the gene targeting profiles of cells treated with 
the two forms of miR-140 are quite different although 
there is a certain level of overlapping target clusters. 
Likewise, the change of signalling pathways by two miR-
140 isoforms is also distinguishable. By using a cut-off of 
1.3-fold change, we were able to identify further targets 
of miR-140 isoforms after the integration of the two high 
throughput datasets of gene and signalling protein profiles. 
Our data show that the majority of these newly identified 
targets cannot be predicted by the conventional in-silico 
prediction tools. There are various potential reasons to 
explain this sort of as-expected mismatch [30, 31]. Firstly, 
the sequence complements of miRNA precursors are often 
not conserved thus beyond the capacity of our current 
computational prediction algorithms which highly relies 
on the conservation of sequence alignment. Secondly, non-
canonical microRNA binding has been frequently observed, 
which also participates regulation of gene expression. 
In addition, integrated approaches of transcriptome and 
proteome data analysis present the advantage of identifying 
those more important or non-direct targets from complicated 
regulation and signalling networks. Despite the distinctive 
targeting or regulating profiles, the two strands of miR-
140 share some targets such as IGF1R and FOS. Increased 
IGF-1R activity is implicated in tumorigenesis and cancer 
cell invasiveness and previous reports have shown that 
IGF1R is one of the targets of miR-140-5p. Our data show 
that miR-104-5p can also decrease gene expression and 
phospho-protein of IGF1R for the first time. The FOS 
gene has been found to overexpressed in several cancer 
types and considered as a proto-oncogene [32]. The FOS 
protein interacts with a panel of other proteins (c-Jun, junB, 
junD, FosB, Fra-1 and Fra-2) and forms the heterodimeric 
complex of Activator Protein-1 (AP-1) transcription factors 
which mediates multiple functions of cancer cells and is 
implicated as a driver of tumorigenesis [33].
In combination with our data and literature, we 
speculate that the two strands of miR-140 show inhibitory 
effect on the behaviour of lung cancer cells in different 
mechanisms (Figure 7). miR-140-3p targets EGFR and 
IGF1R, which leads to the inactivation of the PI3K/AKT 
pathway which is involved in cancer cell survival and 
metabolism. Also, the ERK1 checkpoint in the downstream 
of EGFR and IGF1R is inactivated by miR-140-3p, leading 
to a reduction of active AP-1 proteins including FOS and 
c-JUN, thus modulate invasion and transformation of lung 
cancer cells. MiR-140-3p can also regulate STAT3 directly 
or indirectly through EGFR, which also mediates the 
expression of AP-1 transcription factors such as FOS and 
c-Jun. One of the other targets of miR-140-3p is ITGB3 
which cooperates with EGFR as a complex and is also a 
key factor in tumour cell adhesion and tumour angiogenesis. 
In contrast, miR-140-5p can target IGF1R, leading to 
inactivation of the PI3K/AKT and an ERK1 axis through 
IRS1. miR-140-5p can also target PTEN to attenuate its 
suppression of the PI3K/AKT signalling, suggesting its 
multiple functions to regulate this pathway. Both strands of 
imR-140 can target FOS thus inhibit tumour cell invasion 
and modulate their transformation.
One of the limitations of this study is that the 
effect of ITGB3 downregulation by miR-140-3p needs 
to be further investigated in a tumor microenvironment 
containing other cell types such as stromal cells and 
fibroblasts. There is a report that ITGB3 expression is 
frequently induced by the transforming growth factor 
beta (TGFβ) secreted by the stromal cells, that acts as an 
inducer of the EMT [22, 34]. It will also be interesting to 
evaluate the therapeutic potential of the miR-140 strands 
in an in vivo model and by translational research in future.
In summary, we have demonstrated for the first 
time that miR-140-3p and miR-140-5p both suppress 
the malignant properties of lung cancer cells but through 
distinct and multiple mechanisms. This study provides 
novel insights into the roles of the two forms of pre-
miR-140 products in lung cancer by taking advantage of 
the integrated approaches of RNA-seq after biotin-miRNA 
pull down and high-throughput antibody array.
MATERIALS AND METHODS
Patient tissue specimens
Fresh tissue samples from NSCLC patients were 
collected immediately after surgery and stored at -80°C 
until use by Capital Medical University Hospital, Beijing, 
China. The collection was approved from the Health 
Authority local research ethics committee. The recruited 
patients were informed and participated with a written 
consent. The cohort included 68 unpaired normal and 
tumour tissues with 19 paired normal and tumour lung 
tissues. All the specimens used in the current study were 
verified by a consultant pathologist. Tissues were divided 
in two categories, depending on the availability. Paired 
tissues refers to tissues from the same patients, in which 
the tumour part and the adjacent normal counterpart have 
been resected surgically, whereas the unpaired are tissues 
from different patients. The patient clinic-pathological 
information is described in Table 3.
Cell culture
A549 carcinoma and SK-MES-1 squamous 
carcinoma NSCLC cell lines were obtained from Lonza 
(Gloucestershire, UK) and maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% foetal 
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bovine serum (FBS) and antibiotics (100U/ml) (Gibco, 
Invitrogen, UK). The normal lung cell line BEAS-2B was 
maintained in Bronchial Epithelial Cell Growth Medium 
supplemented with BEGM™ Bullet Kit (Lonza, Slough, 
UK). The primers used for the evaluation of miRNA 
expression was listed in Table 4.
Transient miRNA transfection
Mimics of hsa-miR-140-3p, hsa-miR-140-5p and 
a scramble miR control were purchased from Sigma-
Aldrich (Dorset, UK). A549 and SK-MES-1 cell lines 
were transiently transfected with these miRNA mimics 
using 2 μl/ml of DharmaFECT1 transfection reagent (GE 
Healthcare Dharmacon, Colorado, USA) in antibiotic-free 
medium.
Quantitative real-time polymerase chain reaction 
(qRT-PCR)
Total RNA was extracted from all the cell lines and 
tissues using TRI reagent (Sigma-Aldrich, Dorset, UK) 
according to the manufacturer’s instructions. The total 
RNA samples (500 ng) was converted into cDNA using 
a miRNA-compatible reverse transcription primer and the 
reverse transcription kit (New England BioLabs®, UK). 
The conditions used for reverse transcription were 42°C 
for 60 minutes and 95°C for 5 minutes using Applied 
Biosystems 2720 Thermal Cycler (Life Technologies, 
Paisley, UK). Following reverse transcription, cDNA 
was diluted 1:24 using DEPC water. PCR amplification 
was performed using the SYBR Green JumpStart Taq 
ReadyMix (Sigma-Aldrich, Dorset, UK) and specific 
reverse and forward primers for each miRNA (Sigma-
Aldrich, Dorset) in a IQ5 Bio-Rad qPCR thermocycler. 
Reaction used the following parameters: pre-denaturation 
for 10 minutes at 94°C; followed by 40 cycles of 
denaturation at 94°C for 15 seconds, annealing and 
elongation at 58°C for 1 minute. Results were analysed 
using 2-(ΔΔCT) method of normalisation to housekeeping 
gene U6 or GAPDH in cell lines and U48 in tissues. A 
melting curve analysis was also included.
Transwell invasion assays
Cells were detached using HYQTase Cell 
Detachment Solution (Hyclone, Logan, UT, USA) 24 
hours after being transfected and resuspended in serum-
free media, at a concentration of 1×105 cells/ml. On 
the bottom of each well, 650 μl of medium containing 
10% FCS (chemoattractant) or serum-free media (no 
chemoattractant) were added. Policarbonate 8μm pore 
sized ThinCert™ 24-well plate inserts (Grenier, Bio-One 
GmbH, Austria) were placed in each well and filled with 
500 μl of cell suspension. Chambers were coated with 
serum-free medium containing Matrigel (BD Biosciences, 
NJ USA) to gain a concentration of 500μg/ml. After 24 
hour incubation at 37°C, the inserts were washed with 
PBS and then incubated 1 hour at 37°C in 350μl Cell 
Dissociation Solution (CDS; Sigma Aldrich, Dorset, UK)/
Calcein AM (eBioscience, Hatfield, UK) at a ratio of 1.2 
μl Calcein AM in 1 ml CDS. The cells suspension was then 
transferred into a black 96-well plate and fluorescence was 
measured (excitation 485nm/emission 520nm) using the 
Glomax Multi Detection System (Promega, Wisconsin, 
USA). To analyse the total directed cell movement, the 
wells containing no chemoattractant was subtracted from 
the test wells.
Adhesion assay
A total of 1×104 transfected cells/well were added 
into a 96 well plate coated with 100 μg/well of either 
laminin or collagen. A549 and SK-MES1 were allowed 
to attach at 37°C for 40 and 60 minutes, respectively, then 
washed with PBS, fixed using 200 μl of 4% Formalin and 
incubated at room temperature for 15 mins. Crystal Violet 
0.5% was then added into each well, the plate incubated 
again at room temperature for 10 minutes, washed twice 
with distilled water and finally left overnight at 37°C to 
dry. The following day the absorbance was measured 
using the Glomax Multi Detection System (Promega, 
Wisconsin, USA).
Tubule formation assay
A total of 1.4×105 HUVEC cells/ml in complete 
medium and 100 μl of either A549 or SK-MES1 medium 
were added to each well of a 96-well plate coated with 
serum-free medium containing 50% Matrigel (BD 
Biosciences, NJ USA). 100 μl of 60% diluted tumour 
condition medium from cells treated with miRNA mimics 
was added to each well and the tubule formation was 
monitored for 6 hours in time lapse using the EVOS 
System (Thermo Fisher Scientific, Waltham, MA USA).
Enzyme linked immunosorbent assay (ELISA)
The human vascular endothelial growth factor A 
(VEGF-A) levels in the TCM of A549 cells transfected 
with negative and miR-140-3p mimics were quantified 
by using 96-well plates pre-coated with VEGF-A primary 
antibody by using a specific kit purchased from Aviva 
System Biology, San Diego, USA. Following 24 hours 
of negative and miR-140-3p treatment, the media was 
transferred in a new tube and centrifuged at 1000 xg for 15 
minutes to remove any cellular debris. The samples were 
then processed following the manufacturer’s instructions. 
The absorbance was measured using Glomax Multi 
Detection System (Promega, Wisconsin, USA).
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In silico analysis of miR-140-3p and its targets
To evaluate the putative mRNA targets of miR-140-
3p and miR-140-5p, computational methods (Diana mT, 
miRanda, miRWalk, TargetScan) were used.
MiRNA target validation by using in silico tools
The pmirGLO Dual-Luciferase miRNA Target 
Expression Vector (Promega, Wisconsin, USA) was used 
to evaluate miRNA activity by inserting the putative 
miRNA target sites 3′ of the firefly luciferase gene 
(luc2). The target sites were cloned into the pmiRGLO 
Vector, propagated in the One Shot® TOP10 Chemically 
Competent E. coli cells (Invitrogen, Carlsbad, CA) and 
purified using GenElute™ Plasmid Miniprep Kit (Sigma-
Aldrich, Dorset, UK). Plasmids were partially sequenced 
to verify the integrity of the cloned inserts. Cells were 
transfected with plasmids containing the pmiRGlo vector 
and wild-type and mutated target sequences of miR-140-
3p. After 24 hours cells were analysed for luciferase 
activity using the Dual-Glo® Luciferase Assay System 
(Promega, Wisconsin, USA) and the Glomax Multi 
Detection System (Promega, Wisconsin, USA. Normalised 
firefly luciferase activity (Firefly/Renilla) for each 
construct was compared to that of the pmiRGLO vector 
no-insert control. The primers used for the miRNA target 
validation was listed in Table 4 as well.
Protein microarray (Kinexus)
Following 48 hours of treatment of A549 with 
negative, miR-140-3p and miR-140-5p miRNA mimics, 
cells were lysed as indicated in Section 2.14 and sent 
to Kinexus Bioinformatic Corporation for the analysis. 
Results were sorted in Excel by the lowest % CFC 
(percentage change from control) in response to the 
miRNA treatment.
Western blotting
Following 48 hours of treatment with miR-140-5p 
mimics, cells were lysed using RIPA buffer. The protein 
concentration was determined, an equal volume of 2x 
Llamelli buffer (Sigma Aldrich, Dorset, UK) was added 
and the mixture was heated to 95°C for 5 minutes, then 
loaded on to a gel. Gel was run for 2.5 hours at 100V. Gel 
was transferred onto PVDF membrane using wet transfer 
for 50 minutes, at 500mA. The membrane was blocked in 
5% milk for 1 hour, and probed overnight with the primary 
antibodies. All the primary antibodies used in this study 
were purchased from Santa Cruz Biotechnology (Santa 
Cruz, USA). All the antibodies were diluted 1:200, except 
GAPDH that was diluted 1:1000 Membranes were washed 
three times in TBS-Tween (0.01%) and then probed with 
the appropriate secondary antibody purchased from 
Sigma-Aldrich (Dorset, UK) with a dilution of 1:1000. 
Protein bands were detected using EZ-ECL (Biological 
Industries, Staffordshire, UK) and visualised using a 
G:BOX (Syngene, Cambridge, UK).
Gas chromatography–mass spectrometry 
(GC-MS)
Cells were treated with the microRNA for 24 hours 
and then cells pelleted and stored at -80˚C prior to analysis. 
For metabolite extraction, the cell pellets were sonicated for 
15 minutes after the addition of 500μL of ice cold methanol. 
The supernatant was taken and dried to dryness in a vacuum 
centrifuge. All dried samples were then derivatized by 
addition of 30 μL methoxylamine hydrochloride (15 mg/mL 
in pyridine), followed by incubation at 70°C for 60 min. 
50 μL of MSTFA (Thermo scientific) was then added. The 
samples were then heated at 40°C for a further 90 min. 
Finally, 10 μL of internal standard tetracosane (2 mg/1 
mL in heptane) was added to each vial prior to GC–MS 
analysis. The samples were analysed by injection of 1μl 
of sample onto an Agilent HP5975C GC-MS using a 
Durabond DB-5 column (Length- 30m, diameter 0.250mm 
with a 0.25um film) and a helium carrier gas. A temperature 
gradient was applied holding at 50°C for 2 minutes followed 
by an increase to 300°C at a rate of 10°C per minute. The 
GCMS utilised an electron impact ion source with an 
emission voltage of 70eV, single quadrupole ion separation 
and detection between 50-600amu. The chromatograms 
generated by the GC-MS were then statistically compared 
and the significant compounds identified. All peak areas 
were manually aligned before normalisation to the internal 
standard and metabolites were identified by comparison to 
the NIST library database.
Statistical analysis
D’Agostino-Pearson test was used to verify if the 
data were normally distributed. Unpaired or paired t-test 
was used for data with normal distributions, whereas 
for non-normal distributions, the Mann-Whitney Rank 
Test was applied. When more than two sets of data were 
compared, either One-Way ANOVA or the non-parametric 
Kruskal-Wallis test was used. Graphs and the statistical 
analysis were performed using GraphPad Prism 6.04 
software (GraphPad Software, San Diego, CA, USA). 
Statistical significance was indicated with the following 
nomenclature: *p<0.05, **p<0.01, ***p<0.001.
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